National Institute for Health and Clinical Excellence (NICE)
Involved & informed: good community medicines support
The National Institute for Health and Care Excellence (NICE), in collaboration with several other partner organisations, has launched a new initiative to encourage better medicines support for people who are receiving social care services in their homes.
The aim is to ensure the safe and effective use of medicines in the community, so people get the best possible outcomes with a reduced risk of medicine related harm.
To enable better multi-disciplinary working, the campaign encourages health commissioners and local authorities to have a written agreement that sets out clear responsibilities for home-based medicines support.
Professor Gillian Leng, deputy chief executive and director of health and social care at NICE, yesterday said:
“A collaborative approach to medicines support is key to improving outcomes for people accessing social care services in their homes, and could in turn help to reduce the number of preventable hospital admissions.
“We’re therefore delighted to be working with our partner organisations to highlight how NICE guidance and standards can help health and social care practitioners provide effective, person-centred advice and support about medicines in the community.”
The campaign also urges home care providers to ensure their medicines policies are robust and based on NICE guidance.
Jayne Easterbrook, learning and development/training specialist at the United Kingdom Homecare Association (UKHCA), yesterday said:
“Providing medication support is a really important part of a homecare provider’s responsibilities in supporting people to live well at home. This is why UKHCA is delighted to be part of the Involved & informed: good community medicines support collaboration. Working closely with other stakeholders, who understand the needs of individuals, will support homecare providers to support individuals with medication needs safely.”
These key audiences are: local authority and clinical commissioning group (CCG) commissioners; social workers and other adult Care Act assessors; home care providers; people accessing medicines support (and their families and carers); Care Quality Commission (CQC) inspectors; GPs; pharmacists; and NHS Acute Trusts.
Cllr Ian Hudspeth, Chairman of the Local Government Association’s (LGA’s) Community Wellbeing Board, yesterday said:
“Councils are committed to supporting people to live independently and safely at home.
“The use of medicines for some people receiving care at home is an important part of this. We are pleased to be able to work with NICE and other national partners on this campaign, for the benefit of those who use these services and need medicines support.”
NICE has worked with several partner organisations on this campaign: the Association of Directors of Adult Social Services (ADASS), the Local Government Association (LGA), United Kingdom Homecare Association (UKHCA), the Care Quality Commission (CQC), Voluntary Organisations Disability Group (VODG), Think Local Act Personal (TLAP), NHS England, Skills for Care, Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners (RCGP).
Partner organisations will be sharing these messages with frontline colleagues through social media, bulletins and targeted emails.
Andy Tilden, Skills for Care Interim CEO, yesterday said:
“Skills for Care are pleased to have been a partner in developing this campaign as we know safe and appropriate medicines support for people living in their own homes is a vital aspect of high-quality care and support.
“Home care providers who want to improve safety and staff confidence levels can use this campaign to ensure that their medicines policies are robust with content based on NICE guidance.”
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Wireless device recommended for treating people with overactive bladder14/02/2020 12:15:00
Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years
Researchers wanted to study the public’s views of health-related quality of life13/02/2020 11:15:00
Researchers have been asked to express their interest in running a study of the UK public’s valuation of health-related quality of life.
Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine05/02/2020 14:15:00
NICE yesterday (4 February 2020) published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.
Broader types of data to be used in development of NICE guidance04/02/2020 16:15:00
An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact of our guidance.
NICE publishes updated principles31/01/2020 15:25:00
NICE has published a simple guide to the way we develop our guidance and standards.
Nasal spray medicine for treatment-resistant depression not recommended by NICE29/01/2020 11:15:00
More evidence on the clinical and cost effectiveness of esketamine needed.
Digital and mobile interventions could support regular health services in helping people stop smoking and reduce their risk of obesity, says NICE24/01/2020 11:15:00
Health professionals can consider digital and mobile interventions as a supplement to regular services to support behaviour change in people at risk of developing chronic conditions.
Care matters – Working together to get support right for adult carers23/01/2020 11:15:00
Dame Philippa Russell, Vice-President of Carers UK and Topic Adviser for the NICE guideline on Supporting Adult Carers.
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs17/01/2020 14:10:00
Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t be recommended for use in the NHS because at its current price, it doesn’t have the potential to be cost-effective.